One thing in the presentation that I hadn't noticed before:
The lung cancer preclinical (which is probably being partnered) will be Zantrene + PD-1 inhibitor.
Phil has improved out of sight from the early days.
I'm not sure of the target audience. If I was new to RAC, this presentation wouldn't sell it to me by itself. The story takes many days of full-time DD for a new investor. But it's fine if the aim is to persuade existing investors to top up, e.g. in the SPP.
Ann: Race investor briefing & updated presentation, page-299
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
0.040(2.74%) |
Mkt cap ! $255.5M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.52 | $1.46 | $104.7K | 70.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 435 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.50 | 4882 | 3 |
View Market Depth
| Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |